Neurology : Rituximab as treatment Infectious Diseaseor anti-MuSK myasthenia gravis: Multicenter blinded prospective review is organized by American Academy of Neurology (AAN) and will be held during Sep 05, 2017 - Sep 05, 2020. This CME Conference has been approved FOR a maximum of 0.75 AMA PRA Category 1 Credits.
Conference Objectives are :
Upon completion of the article by Hehir et al, the participant should be able to:
• State the most common sex and relative age for patients with anti-MUSK myasthenia gravis in study
• State what percentage of rituximab-treated patients in this study met the primary outcome
• State what secondary outcomes from rituximab treatment were met during this review
Additional details will be posted as soon as they are available.